Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Alzheimer’s Disease Treatment Market Revenue Growth On Track For A 6.6% CAGR Through 2030
The alzheimer’s disease treatment market size has demonstrated substantial growth in recent years. It is anticipated to expand from $6.94 billion in 2025 to $7.37 billion in 2026, at a compound annual growth rate (CAGR) of 6.2%. Historically, this growth can be ascribed to the increasing prevalence of alzheimer’s disease, an aging global population, limited availability of effective therapies, growing awareness regarding cognitive disorders, and the rising healthcare infrastructure for neurological diseases.
The Alzheimer’s disease treatment market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $9.51 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This projected growth during the forecast period is driven by factors such as the advancement of beta-amyloid targeted immunotherapies, the broader availability of monoclonal antibody treatments, the increasing use of combination therapies, the rise of home care and telemedicine services for Alzheimer’s patients, and increased funding for early detection and diagnostic biomarkers. Key developments expected during this period include a surge in investment in immunotherapy and monoclonal antibodies, a greater embrace of multi-pathway combination drugs, an increase in early diagnosis and biomarker-guided treatments, a heightened focus on preserving cognitive function and enhancing memory, and the incorporation of home-based care and remote monitoring for Alzheimer’s patients.
Get A Free Sample Report With In-Depth Market Insights:
Alzheimer’s Disease Treatment Market Growth Backed By Core Demand Fundamentals
Government-led efforts are projected to boost the expansion of the Alzheimer’s disease treatment market. Such initiatives involve governmental plans or actions designed to tackle particular problems or issues, drawing funding from diverse sources like taxes, grants, and donations. In the context of Alzheimer’s disease treatment, these initiatives support research endeavors, specifically clinical trials for novel drugs and therapies. For example, the American Medical Association, a US-based professional organization, reported in April 2025 that U.S. health spending surged by 7.5% to reach $4.9 trillion, equating to $14,570 per capita in 2023, a rise that exceeded the 4.6% increase recorded in 2022. Consequently, these governmental endeavors are a primary catalyst for the expansion of the Alzheimer’s disease treatment market.
Alzheimer’s Disease Treatment Market Segment Performance And Emerging Opportunities
The alzheimer’s disease treatment market covered in this report is segmented –
1) By Drug Class: Cholinergic, Memantine, Combined Drug, AChE inhibitors, Immunoglobulins
2) By Drug Type: Cholinesterase Inhibitors, NMDA Receptor Antagonists
Subsegments:
1) By Cholinergic: Donepezil, Galantamine, Rivastigmine
2) By Memantine: Memantine Hydrochloride, Extended-Release Memantine
3) By Combined Drug: Donepezil and Memantine Combination
4) By AChE Inhibitors: Tacrine, Physical Inhibitors
5) By Immunoglobulins: IVIG (Intravenous Immunoglobulin), Monoclonal Antibodies
Alzheimer’s Disease Treatment Market Growth Trends Reshaping The Competitive Landscape
Leading companies operating within the Alzheimer’s disease treatment market are concentrating on achieving regulatory approvals to gain a competitive advantage and enhance their product offerings. Regulatory approvals signify the formal authorization granted by government agencies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), for a product to be commercially marketed and sold to the public. For instance, in July 2024, Eli Lilly and Company, a US-based pharmaceutical company, obtained FDA approval for its Alzheimer’s treatment, Kisunla (donanemab-azbt), which is indicated for adults with early symptomatic Alzheimer’s disease, including those experiencing mild cognitive impairment and mild dementia. The drug is delivered via monthly intravenous infusion and has demonstrated effectiveness in slowing the progression of the disease in clinical trials. The approval reflects its potential impact, having received Fast Track, Priority Review, and Breakthrough Therapy designations.
Alzheimer’s Disease Treatment Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the alzheimer’s disease treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Merck Sharp & Dohme Corp., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., UCB S.A., Eisai Co. Ltd., Forest Laboratories LLC, Ono Pharmaceutical Co. Ltd., H. Lundbeck A/S, Allergan plc, Luye Pharma Group, Avanir Pharmaceuticals Inc., Denali Therapeutics Inc., Athira Pharma Inc., ProMIS Neurosciences Inc., AC Immune SA, vTv Therapeutics Inc., AB Science SA, TauRx Pharmaceuticals Ltd., Alzheon Inc.
View The Full Alzheimer’s Disease Treatment Market Report:
Alzheimer’s Disease Treatment Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America is the largest region in the Alzheimer’s disease treatment market in 2025. Middle East is expected to be the fastest growing region in the Alzheimer’s disease treatment market share during the forecast period. The regions covered in the alzheimer’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
